Skip to content

The clinical appliacation of Synthetic MRI in nasopharyngeal carcinoma

The feasibility of Synthetic MRI in diagnosis and efficacy evaluation of nasopharyngeal carcinoma and its prognostic value: an open-labeled, prospective study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020358
Enrollment
Unknown
Registered
2018-12-25
Start date
2018-12-24
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

Gold Standard:conventional series of the 3.T Magnetic Resonace(T1WI,T2WI,DWI,T1WI+C)
Index test:Synthetic&#32
MRI&#32
(T1WI,&#32
T1WI+C)

Sponsors

Department of Radiology, Sun Yat-Sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients between 18-65 years old; 2. ECOG score 0-1; 3. Patients with newly histologically confirmed nasopharyngeal carcinoma without any history of anti-tumor therapy or other malignancies; 4. With normal bone marrow, liver and renal function 14 days before enrollment as followed: 1) HGB = 9g/dL; 2) ANC > 1.5*10^9/L, PLT > 100*10^9/L , TBIL< 1.5xULN; ALT and AST < 2×ULN; PT/APTT < 1.5×ULN; Creatinine clearance < 1.5xULN; 5. Patients must offer signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients have received anti-tumor therapy, including chemotherapy, radiotherapy and surgery; 2. Patients have been or suspicious to be allergic to MR contrast or metal; 3. Patients have MR contraindications, including those individuals with pacemaker implantation, magnetic materials in the body or other situations that could not get close to the high-intensity magnetic field; 4. Patients have experienced claustrophobia; 5. In pregnant or lactating Female; 6. Patients could not cooperate with follow-up because of the following reasons, such as psycology, society, family or geography; 7. With severe uncontrolled infections (>grade 2, NCI-CTC v.4.0); 8. Patients with history of heart disease: congestive heart-failure > NYHA grade 2, active coronary heart disease (patients suffered from myocardial infarction 6 months before enrollment could be accepted), arrhythmia that needs anti-arrhythmia therapy (beta receptor blocker and digoxin could be accepted) or uncontrolled hypertension; 9. Patients have diseases that might influence the drug administration, distribution, metabolization or excretion; 10. Patients have the history of other malignancies; 11. Patients without signing informed consent.

Design outcomes

Primary

MeasureTime frame
Diagnosis quality of the overall images;

Secondary

MeasureTime frame
Readability evaluation;incidence rate of the artifact;Odds Ratio;hazard ratio;area under curve;

Countries

China

Contacts

Public ContactChuanmiao Xie

Sun Yat-Sen University Cancer Center

xiechm@sysucc.org.cn+86 020 87343218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026